Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-20
DOI
10.1038/s41598-019-53356-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Battle of GLP-1 delivery technologies
- (2018) Minzhi Yu et al. ADVANCED DRUG DELIVERY REVIEWS
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- IN SITU FORMING DEPOTS AS SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
- (2018) Navjot Kanwar et al. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
- Clinical pharmacology of glucagon-like peptide-1 receptor agonists
- (2018) Dimitrios Sfairopoulos et al. Hormones-International Journal of Endocrinology and Metabolism
- Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia
- (2018) Claire Muller et al. International Journal of Stroke
- Long-Acting Release Microspheres Containing Novel GLP-1 Analog as an Antidiabetic System
- (2018) Sida Ruan et al. MOLECULAR PHARMACEUTICS
- What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis
- (2018) Dilan Athauda et al. Journal of Parkinsons Disease
- Incretin drugs as modulators of atherosclerosis
- (2018) Enrique Gallego-Colon et al. ATHEROSCLEROSIS
- Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
- (2018) James G. Boyle et al. CLINICAL SCIENCE
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
- (2018) Raffaella Gentilella et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
- (2018) Shuchun Chen et al. Scientific Reports
- Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
- (2018) Miaad Bader et al. NEUROBIOLOGY OF DISEASE
- The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate
- (2017) Barry E. Gidal et al. EPILEPSY RESEARCH
- Exenatide: pharmacokinetics, clinical use, and future directions
- (2017) Filip K. Knop et al. EXPERT OPINION ON PHARMACOTHERAPY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration
- (2017) Lital Rachmany et al. Scientific Reports
- Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4
- (2016) David Tweedie et al. Alzheimers & Dementia
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program
- (2016) Hui Peng et al. Current Diabetes Reports
- Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
- (2016) M. Nauck DIABETES OBESITY & METABOLISM
- Investigational glucagon-like peptide-1 agonists for the treatment of obesity
- (2016) Brian Tomlinson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying
- (2016) Feng Wan et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
- (2016) Suk Chon et al. Diabetes & Metabolism Journal
- Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury
- (2014) Nigel H. Greig et al. Alzheimers & Dementia
- Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study
- (2014) Namyi Gu et al. CLINICAL THERAPEUTICS
- Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis
- (2014) Jacqueline A. Koehler et al. DIABETES
- Injectable controlled release depots for large molecules
- (2014) Steven P. Schwendeman et al. JOURNAL OF CONTROLLED RELEASE
- The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
- (2014) Stephen C. Bain Diabetes Therapy
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Nonhuman Primate Models in the Genomic Era: A Paradigm Shift
- (2013) E. J. Vallender et al. ILAR JOURNAL
- Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
- (2013) Katharine Eakin et al. PLoS One
- Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice
- (2012) David Tweedie et al. EXPERIMENTAL NEUROLOGY
- Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
- (2011) Seema Briyal et al. BRAIN RESEARCH
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nutritional regulation of glucagon-like peptide-1 secretion
- (2008) Gwen Tolhurst et al. JOURNAL OF PHYSIOLOGY-LONDON
- Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys
- (2007) G AI et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now